Tristetraprolin Upregulation Reduces Frailty and Increases Bone Density in Old Mice
This study discusses the impact of lifelong tristetraprolin (TTP) upregulation on reducing frailty and enhancing bone mineral density in aged mice. TTP plays a role in suppressing pro-inflammatory cytokines, such as TNF-α, suggesting a decrease in age-related inflammation as a contributing factor to the observed improvements. The study explores whether TTP upregulation offers a more targeted approach to inhibiting TNF-α signaling compared to current anti-TNF-α therapies, potentially allowing for a balanced immune response to injury and infection.
A novel transgenic mouse model (TTP knock-in – TTPKI) with elevated TTP was used to assess long-term bone health benefits. Physical assessments, bone histomorphometry, and immune cell analysis were conducted on TTPKI and wild-type mice. Results showed improved bone health, reduced frailty, and restored immune cell composition in aged TTPKI mice. The findings suggest that heightened TTP expression can promote a healthier aging phenotype.
Link: https://www.iadr.org/about/news-reports/press-releases/enhanced-stability-tristetraprolin-promotes-bone-health-and
